ArticleStem cell research & therapy2025
Transplantation of UC-MSCs in ovary improves ovarian function and intermediate outcomes in IVF/ICSI cycles of POI patients: a clinical cohort study.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Restoring glucose metabolic homeostasis to attenuate ovarian aging: mechanisms and clinical prospects.Journal of ovarian research · 2026Review
- Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles from different tissue sources on diminished ovarian reserve and the related mechanisms.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the clinical outcomes of umbilical cord mesenchymal stem cell (UC-MSC) transplantation on ovarian function in women with premature ovarian insufficiency (POI), and its potential to improve in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) outcomes.
methodsA clinical cohort study was conducted at the Reproductive Medicine Center of Nanjing Drum Tower Hospital from 2019 to 2023. The study included POI patients who underwent either UC-MSC ovarian tissue injection or traditional IVF/ICSI-FET treatment. UC-MSCs were isolated from Wharton's jelly of the umbilical cord, cultured, and transplanted into the ovaries of patients via transvaginal ultrasound-guided injection. The embryo freezing rate, number of oocytes retrieved, and ovarian function indicators (e.g., serum FSH levels, antral follicle count (AFC)) were compared between the UC-MSC-treated group and the traditional IVF/ICSI-FET group.
resultsA total of 71 POI patients were included, with 43 in the UC-MSC group and 28 in the IVF/ICSI-FET control group. After treatment, the AFC in the UC-MSC group was significantly higher compared to the control group (3.86 ± 2.93 vs. 2.39 ± 1.66, p = 0.019). Furthermore, the number of oocytes retrieved in the initial controlled ovarian hyperstimulation (COS) cycle following treatment was significantly greater in the UC-MSC group (1.88 ± 1.00 vs. 1.39 ± 1.13, p = 0.034). Patients undergoing UC-MSC treatment exhibited a substantial increase in the number of oocytes retrieved in their first COS cycle compared to their pre-treatment cycle (1.88 ± 1.00 vs. 1.28 ± 1.01, p = 0.007). Additionally, the number of frozen embryos significantly increased (0.74 ± 0.82 vs. 0.14 ± 0.41, p < 0.001), and the proportion of cycles resulting in frozen embryos was notably higher (55.81% vs. 11.63%, p < 0.001). Further Gene Set Enrichment Analysis (GSEA) revealed that genes expression in ovarian hormones and estrogen related signaling pathways were up-regulated following UC-MSCs therapy.
conclusionUC-MSC ovarian tissue injection is a promising therapeutic strategy for improving clinical outcomes in IVF/ICSI cycles for women with POI. The use of UC-MSCs may offer a novel and effective alternative to conventional infertility treatments for POI patients, especially those seeking genetic offspring. Further studies are required to explore the long-term safety and efficacy of this treatment in larger, multi-center trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.